Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Subcortical atrophy and cognition: Sex effects in multiple sclerosis.
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Elevation of Ser9 phosphorylation of GSK3β is required for HERV-W env-mediated BDNF signaling in human U251 cells.
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Ximino
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.
Glial contributions to neural function and disease.
Exome sequencing in single cells from the cerebrospinal fluid in multiple sclerosis.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Overview of treatment options in multiple sclerosis.
Catheter venography and endovascular treatment of chronic cerebrospinal venous insufficiency.
Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study.
The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Biomarkers in multiple sclerosis.
Serum level of interleukin-6 in Chinese patients with multiple sclerosis.
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
Rehabilitation in transverse myelitis.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Pages
« first
‹ previous
…
133
134
135
136
137
138
139
140
141
…
next ›
last »